2LOOP TECH Spółka z Ograniczoną Odpowiedzialnością (KRS 0000430992, NIP 7010351673) is a Polish company, headquartered in Warszawa, Mazowieckie voivodeship. 2LOOP TECH operates in: Other research and experimental development on natural sciences and engineering (PKD 72.19.Z). Industry: Research and development. The company has been listed in the National Court Register since August 24, 2012. 2LOOP TECH's most recently reported net revenue was 0 PLN for 2019.
No reported revenue
The company reported no revenue in any available reporting year. This may indicate a non-operating entity.
No arrears identified in the analyzed sources
No arrears or bankruptcy proceedings identified in the analyzed sources.
Business profile - 2LOOP TECH
Identity
- Name
- 2LOOP TECH Spółka z Ograniczoną Odpowiedzialnością
- Legal form
- SPÓŁKA Z OGRANICZONĄ ODPOWIEDZIALNOŚCIĄ
- Founded
- August 24, 2012
- Registry status as of
- November 21, 2025
- Latest entry
- April 20, 2021
- Founding act
- 24-08-2012
Articles of association history (2)
- 24-08-2012
- 19-01-2021 R., ZMIANA: §1 - §6, §10, §14 - §16.
Activities
Main activity
72.19.ZOther research and experimental development on natural sciences and engineering
Other activities
Address and contact
- Address
- UL. MIODOWA, 1, 00-080, WARSZAWA, POLSKA
- Voivodeship
- MAZOWIECKIE
- District
- WARSZAWA
- BIURO@2LOOP.TECH
- Website
- WWW.2LOOP.TECH
- E-delivery address
- Not disclosed in the registry
- Coordinates
- 52.2298, 21.0117approx.
Risk and payment profile - 2LOOP TECH
Credibility rating
55.8 / 100
Average credibility
Insolvency risk
Very low
Low threat
Closure risk
3
/ 100
Risk comparison - scale 0 (safe) → 100 (critical)
Organizational stability signals
No instability signals - ownership, management, PKD codes and company name remain relatively stable.
Shareholder changes
2
2/14 yrs
Board changes
3
3/14 yrs
PKD changes
2
2/14 yrs
Name changes
1
1/14 yrs
Data from 14 years of registry activity.
Credibility history
Payment reliability score from 2018–2019
Current: C (56/100)
Trend: stable (+1.0 pts/year)
Moderate payment credibility - the company is able to meet its obligations, but some indicators warrant caution.
Trade credit limit history
Standard limit from 2018–2019
Current: 0 PLN
Safe: 0 PLN
Difference between risk models
Closure - probability of ceasing operations (operational continuity). Insolvency - probability of formal bankruptcy / restructuring. The models use different data - results can diverge significantly when balance-sheet data is incomplete.
Operational status - 2LOOP TECH
Founded
August 24, 2012
13 years in operation
Legal form
SPÓŁKA Z OGRANICZONĄ ODPOWIEDZIALNOŚCIĄ
Registry: RejP
Headquarters
WARSZAWA
MAZOWIECKIE
Primary PKD
72.19.Z
Other research and experimental development on natural sciences and…
Share capital
300.0 K PLN
3,000 shares total
Shareholders
3
shareholders
Board
1 person
Proxies: 2
Filed years
2 years
2018–2019
Registry entries
17
latest: April 20, 2021
Revenue
0 PLN
2019
Net profit
0 PLN
2019
Assets
5.0 K PLN
2019
Equity
5.0 K PLN
2019
Companies in the same location
Public procurement
Trademarks
Reviews
Rate business credibility - 2LOOP TECH.
No ratings
Related articles
News
Bioceltix in the final EMA dialogue phase: BCX-CM-J could become Europe's first veterinary cell-therapy drug for dogs
Wrocław-based Bioceltix S.A. (KRS 0000744521) entered Q2 2026 in the final EMA dialogue phase regarding BCX-CM-J - Europe's first veterinary cell-therapy drug from mesenchymal stem cells for dogs with osteoarthritis. Responses to the final EMA questions are due in May 2026; the CVMP recommendation and marketing authorisation are possible in Q3/Q4 2026. Pre-commercial biotech: 2024 closed with a PLN 14.9 m loss on zero revenue; cash of PLN 33.6 m at year-end. Trigon DM maintained a buy rating with a price target of PLN 127.2.
News
Captor Therapeutics: PLN 36 m of cash at 30 September 2025, runway to mid-2026 - clinical data versus the cash clock
Wrocław-based Captor Therapeutics S.A. (KRS 0000756383) - a pre-commercial biotech specialising in TPD (Targeted Protein Degradation) - closed Q3 2025 with PLN 36 m of cash and grants securing financing to mid-2026. CT-01 (hepatocellular carcinoma) entered Phase I - the first patient dosed at Barcelona Clinic Liver Cancer. CT-03 (MCL-1 degrader) nearing clinical entry. Without a new R&D partnership or equity issuance in 2026, the company will need additional financing.
